NFSG
KNSA icon

Newbridge Financial Services Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Newbridge Financial Services Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-300
Closed -$5.26K – 1243
2023
Q4 		$5.26K Buy
+300
New +$4.93K ﹤0.01% 853

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Newbridge Financial Services Group's KNSA Position: Q1 2024 in Review

Newbridge Financial Services Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2024, closing a stake of 300 shares — an estimated $5.26K sold.

Newbridge Financial Services Group first reported a position in KNSA in Q4 2023 and held it in 1 quarter. The position peaked at $5.26K in Q4 2023. 154 funds tracked by Wall St. Rank hold KNSA as of Q1 2024.

  • Newbridge Financial Services Group reported no remaining Kiniksa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Newbridge Financial Services Group sold 300 Kiniksa Pharmaceuticals shares in Q1 2024, an estimated $5.26K.
  • Newbridge Financial Services Group first reported a position in Kiniksa Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Newbridge Financial Services Group's Kiniksa Pharmaceuticals position peaked at $5.26K in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2024.

Based on Newbridge Financial Services Group's 13F filing for Q1 2024, filed 24 Apr 2024.